Control of Lipids at Baseline in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial

Documenti analoghi

• Relationships of Obesity and Fat Distribution With atherothrombotic Risk Factors: Baseline Results From the Bypass angioplasty Revascularization Investigation 2 Diabetes (BaRI 2D) Trial
  di: Albu, Jeanine B., et al.
  Pubblicazione: (2009)
• Rosiglitazone and Outcomes for Patients with Diabetes and Coronary Artery Disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial
  di: Bach, Richard G., et al.
  Pubblicazione: (2013)
• Relation of Severe Coronary Artery Narrowing to Insulin or Thiazolidinedione Use in Patients With Type 2 Diabetes Mellitus (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes Study)
  di: Pop-Busui, Rodica, et al.
  Pubblicazione: (2009)
• The effect of age on clinical outcomes and health status in the Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial (BARI 2D)
  di: Chung, Sheng-Chia, et al.
  Pubblicazione: (2011)
• Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort
  di: Pop-Busui, Rodica, et al.
  Pubblicazione: (2009)